CO2017010510A2 - Tableta de ribociclib - Google Patents

Tableta de ribociclib

Info

Publication number
CO2017010510A2
CO2017010510A2 CONC2017/0010510A CO2017010510A CO2017010510A2 CO 2017010510 A2 CO2017010510 A2 CO 2017010510A2 CO 2017010510 A CO2017010510 A CO 2017010510A CO 2017010510 A2 CO2017010510 A2 CO 2017010510A2
Authority
CO
Colombia
Prior art keywords
ribociclib
tablet
coating
present disclosure
coated
Prior art date
Application number
CONC2017/0010510A
Other languages
English (en)
Spanish (es)
Inventor
Bindhumadhavan Gururajan
Arnaud Grandeury
Rui Costa
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55806565&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO2017010510(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CO2017010510A2 publication Critical patent/CO2017010510A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CONC2017/0010510A 2015-04-16 2017-10-13 Tableta de ribociclib CO2017010510A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562148240P 2015-04-16 2015-04-16
PCT/IB2016/052136 WO2016166703A1 (en) 2015-04-16 2016-04-14 Ribociclib tablet

Publications (1)

Publication Number Publication Date
CO2017010510A2 true CO2017010510A2 (es) 2018-03-20

Family

ID=55806565

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2017/0010510A CO2017010510A2 (es) 2015-04-16 2017-10-13 Tableta de ribociclib

Country Status (29)

Country Link
US (6) US10799506B2 (enExample)
EP (3) EP4197530B1 (enExample)
JP (1) JP2018514523A (enExample)
KR (2) KR102750931B1 (enExample)
CN (2) CN107530292B (enExample)
AR (1) AR104257A1 (enExample)
AU (5) AU2016248017A1 (enExample)
BR (1) BR112017021283A2 (enExample)
CA (1) CA2982425C (enExample)
CL (1) CL2017002593A1 (enExample)
CO (1) CO2017010510A2 (enExample)
DK (1) DK3283058T3 (enExample)
EA (1) EA201792290A1 (enExample)
EC (1) ECSP17075052A (enExample)
ES (1) ES2938261T3 (enExample)
FI (1) FI3283058T3 (enExample)
HR (1) HRP20230053T1 (enExample)
HU (1) HUE061213T2 (enExample)
IL (1) IL254818A0 (enExample)
MX (1) MX2017013350A (enExample)
PE (1) PE20180035A1 (enExample)
PH (1) PH12017501820A1 (enExample)
PL (1) PL3283058T3 (enExample)
PT (1) PT3283058T (enExample)
SG (1) SG11201708084PA (enExample)
SI (1) SI3283058T1 (enExample)
TN (1) TN2017000422A1 (enExample)
TW (1) TW201642864A (enExample)
WO (1) WO2016166703A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102750931B1 (ko) * 2015-04-16 2025-01-09 노파르티스 아게 리보시클립 정제
CA3048036A1 (en) 2018-07-02 2020-01-02 Apotex Inc Novel crystalline form of ribociclib succinate
CN118986983A (zh) 2019-08-26 2024-11-22 阿尔维纳斯运营股份有限公司 用四氢萘衍生物作为雌激素受体降解剂的治疗乳腺癌的方法
EP4077331A4 (en) 2019-12-16 2023-12-27 Lunella Biotech, Inc. SELECTIVE CDK4/6 INHIBITOR CANCER THERAPEUTICS
BR112022011851A2 (pt) 2019-12-16 2022-09-06 Lunella Biotech Inc Terapêutica de câncer inibidor de cdk4/6 seletivo
CA3187241A1 (en) * 2020-08-03 2022-02-10 Krishna Murthy Bhavanasi Pharmaceutical compositions comprising ribociclib
CA3191478A1 (en) * 2020-09-29 2022-04-07 Paola Yazmin Ollervides Rubio Pharmaceutical combinations of statins and fibrates for the treatment and prevention of hyperlipidemias and cardiovascular disease
WO2022162122A1 (en) 2021-01-29 2022-08-04 Biotx.Ai Gmbh Genetically verified netosis inhibitor for use in the treatment of a sars-cov2 infection
CN117396208A (zh) 2021-07-16 2024-01-12 达纳－法伯癌症研究所公司 细胞周期蛋白依赖性激酶4/6(cdk4/6)和ikzf2(helios)的小分子降解剂及其使用方法
TWI848533B (zh) 2022-01-25 2024-07-11 瑞士商諾華公司 瑞博西尼藥物組成物
CN120112291A (zh) 2022-08-31 2025-06-06 阿尔维纳斯运营股份有限公司 雌激素受体降解剂的给药方案
EP4626890A1 (en) 2022-12-01 2025-10-08 KRKA, d.d., Novo mesto Ribociclib salts and formulations thereof
TW202440113A (zh) 2023-03-27 2024-10-16 瑞士商諾華公司 治療早期乳癌之方法
WO2025219830A1 (en) 2024-04-15 2025-10-23 Novartis Ag Pharmaceutical compositions of ribociclib

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5428812A (en) * 1977-08-09 1979-03-03 Yoshitomi Pharmaceut Ind Ltd Preparation of coated tablet
JP3672314B2 (ja) * 1994-07-12 2005-07-20 バーウィンド・ファーマスーティカル・サーヴィスィーズ・インコーポレーテッド 防湿性フィルム被覆材組成物、方法および被覆成形物
GB9414045D0 (en) 1994-07-12 1994-08-31 Berwind Pharma Service Moisture barrier film coating composition, method, and coated form
US6448323B1 (en) * 1999-07-09 2002-09-10 Bpsi Holdings, Inc. Film coatings and film coating compositions based on polyvinyl alcohol
SI2331547T1 (sl) 2008-08-22 2014-11-28 Novartis Ag Pirolopirimidinske spojine kot CDK inhibitorji
US8807979B2 (en) * 2009-09-24 2014-08-19 Mcneil-Ppc, Inc. Machine for the manufacture of dosage forms utilizing radiofrequency energy
AR083797A1 (es) * 2010-11-10 2013-03-20 Novartis Ag Succinato de dimetil-amida del acido 7-ciclopentil-2-(5-piperazin-1-il-piridin-2-il-amino)-7h-pirrolo-[2,3-d]pirimidin-6-carboxilico, proceso para prepararla, intermediarios de dicha sintesis y proceso de preparacion de los mismos
SI2673266T1 (sl) * 2011-02-11 2016-11-30 Wista Laboratories Ltd. Fenotiazin diaminijeve soli in njihova uporaba
WO2014011220A2 (en) * 2012-07-13 2014-01-16 Gtx, Inc. A method of treating androgen receptor (ar)-positive breast cancers with selective androgen receptor modulator (sarms)
EP3251673A1 (en) * 2012-12-13 2017-12-06 IP Gesellschaft für Management mbH Combination therapy comprising a cdk4/6 inhibitor and a pi3k inhibitor for use in the treatment of cancer
WO2014097125A1 (en) * 2012-12-20 2014-06-26 Novartis Ag Pharmaceutical combination comprising binimetinib
MY181085A (en) * 2013-03-21 2020-12-17 Novartis Ag Combination therapy
EP2810644A1 (en) * 2013-06-06 2014-12-10 Ferrer Internacional, S.A. Oral formulation for the treatment of cardiovascular diseases
KR102750931B1 (ko) * 2015-04-16 2025-01-09 노파르티스 아게 리보시클립 정제
CN109953966A (zh) * 2017-12-26 2019-07-02 天津耀辰实业发展有限公司 一种含有瑞博西尼的药物组合物及其制备方法
JP7347388B2 (ja) 2020-09-25 2023-09-20 信越化学工業株式会社 紫外線硬化型有機変性シリコーン組成物および硬化物

Also Published As

Publication number Publication date
EP3283058B1 (en) 2022-11-16
JP2018514523A (ja) 2018-06-07
TW201642864A (zh) 2016-12-16
US20250127785A1 (en) 2025-04-24
CA2982425A1 (en) 2016-10-20
US20200390771A1 (en) 2020-12-17
IL254818A0 (en) 2017-12-31
CN115554257A (zh) 2023-01-03
CN107530292A (zh) 2018-01-02
AU2019201929B2 (en) 2020-07-09
SI3283058T1 (sl) 2023-03-31
EA201792290A1 (ru) 2018-02-28
AU2019201929A1 (en) 2019-04-11
AU2020250190A1 (en) 2020-11-05
FI3283058T3 (fi) 2023-03-01
US20250090531A1 (en) 2025-03-20
CL2017002593A1 (es) 2018-05-18
ES2938261T3 (es) 2023-04-05
HUE061213T2 (hu) 2023-05-28
DK3283058T3 (da) 2023-02-13
US20230104792A1 (en) 2023-04-06
WO2016166703A1 (en) 2016-10-20
PL3283058T3 (pl) 2023-03-20
SG11201708084PA (en) 2017-10-30
CA2982425C (en) 2023-10-31
EP3283058A1 (en) 2018-02-21
TN2017000422A1 (en) 2019-01-16
CN107530292B (zh) 2022-11-01
US10799506B2 (en) 2020-10-13
AU2024227794A1 (en) 2024-11-21
US20250134893A1 (en) 2025-05-01
EP4620458A3 (en) 2025-10-22
KR102750931B1 (ko) 2025-01-09
BR112017021283A2 (pt) 2018-06-26
PH12017501820A1 (en) 2018-04-23
US12064434B2 (en) 2024-08-20
MX2017013350A (es) 2018-01-25
AU2022215155A1 (en) 2022-09-01
AU2022215155B2 (en) 2024-08-01
EP4197530B1 (en) 2025-11-12
AR104257A1 (es) 2017-07-05
AU2016248017A1 (en) 2017-10-19
KR20170137101A (ko) 2017-12-12
EP4620458A2 (en) 2025-09-24
PE20180035A1 (es) 2018-01-09
PT3283058T (pt) 2023-02-03
ECSP17075052A (es) 2018-02-28
US12419894B2 (en) 2025-09-23
US20180071292A1 (en) 2018-03-15
HRP20230053T1 (hr) 2023-03-03
EP4197530A1 (en) 2023-06-21
KR20250009572A (ko) 2025-01-17

Similar Documents

Publication Publication Date Title
CO2017010510A2 (es) Tableta de ribociclib
EP3652650A4 (en) TECHNIQUES FOR MANAGING ACCESS TO A HARDWARE ACCELERATOR MEMORY
BR112016013502A2 (pt) unidade de dosagem sólida que desintegra oralmente contendo um componente de estetrol.
BR112018013462A2 (pt) métodos de fabricação de aditivo para adesivos e artigos adesivos
EP2986681A4 (en) An aqueous coating composition
BR112016012615A8 (pt) sistemas, e kit
DK3582780T3 (da) Aminopyrimidinforbindelser, der er anvendelige som SSAO-inhibitorer
BR112015032445A2 (pt) componente semicondutor orgânico
BR112017012406A2 (pt) formulação com relação fixa de insulina glargina/lixisenatida
PH12016500626B1 (en) Film coated tablet containing choline alfoscerate and process for preparing the same
WO2014204881A8 (en) Delayed release cysteamine bead formulation
CL2016002338A1 (es) Uso de un compuesto que es ácido r-2-4-2-etoxi-3-4-trifluorometilfenoxipropil-tio-2-metilfenoxi acético, para el tratamiento de una enfermedad colestásica intrahepática .
MX2015014958A (es) Nuevos derivados de triazolona o sales de la misma y composicion farmaceutica que comprende a la misma.
BR112015024703A2 (pt) formulação farmacêutica, método de tratamento e/ou prevenção de restenose e kit para o tratamento e/ou prevenção de restenose
MX378432B (es) Componente plàstico recubierto con una capa integrada de pvd.
GB2543709A (en) Pharmaceutical agent
BR112017011658A2 (pt) acesso à memória por sistemas de processador duplo
EP3618837A4 (en) MULTI-DIRECTIONAL NUCLEOSIDE DERIVATIVES
EP4385503A3 (en) Enteric coating for soft capsule
EP3481379A4 (en) ORAL GALENIC FORM CONTAINING A QUICK RELEASE EXTERIOR COATING
BR112016006485A2 (pt) composições de liberação pulsátil revestidas por compressão
EP3233797A4 (en) MAP4K4 (HGK) Inhibitors
BR112014018149A8 (pt) Composição melhorada de nitazoxadina e processo para preparar a mesma
EP3642958A4 (en) TIMING EVENT DETECTION
MX2017016392A (es) Conector de enchufe de banda de aleacion de aluminio.